key: cord-0426611-2ow4eb9b
authors: Bozic, Jasminka; Ahmed, Tanvir; Ontsouka, Barthelemy; Fluckiger, Anne-Catherine; Diress, Abebaw; Berthoud, Tamara; Yuan, Xiaoyang; Yang, Lanjian; Diaz-Mitoma, Francisco; Anderson, David E.; Soare, Catalina
title: Use of eVLP-based vaccine candidates to broaden immunity against SARS-CoV-2 variants
date: 2021-09-29
journal: bioRxiv
DOI: 10.1101/2021.09.28.462109
sha: 98e44a64856ec17e0d4cd3c48033ac6cd99b85a6
doc_id: 426611
cord_uid: 2ow4eb9b

Rapid emergence of SARS-CoV-2 variants is a constant threat and a major hurdle to reach heard immunity. We produced VBI-2905a, an enveloped virus-like particle (eVLP)-based vaccine candidate expressing prefusion spike protein from the Beta variant that contains several escape mutations. VBI-2905a protected hamsters against infection with a Beta variant virus and induced high levels of neutralizing antibodies against Beta RBD. In a heterologous vaccination regimen, a single injection of VBI-2905a in animals previously immunized with VBI-2902, a vaccine candidate expressing S from ancestral SARS-CoV-2, hamsters were equally protected against Beta variant infection. As an alternate strategy to broaden immunity, we produced a trivalent vaccine expressing the prefusion spike protein from SARS-CoV-2 together with unmodifed S from SARS-CoV-1 and MERS-CoV. Relative to immunity induced against the ancestral strain, the trivalent vaccine VBI-2901a induced higher and more consistent antibody binding and neutralizing responses against a panel of variants including Beta, Delta, Kappa, and Lambda, with evidence for broadening of immunity rather than just boosting cross-reactive antibodies.

individuals. The following VOC that emerged in South Africa was rapidly identified as a vaccineescape mutant. This Beta variant bears several mutations in its RBD, including E484K and N501Y, which significantly inhibit neutralizing activity elicited against the Ancestral Wu-1 strain of virus whether acquired by vaccination or infection (Tegally et al., 2020; Cele et al., 2021) . Emergence of escape mutants is a major concern because most of the licensed vaccines are based on expression of various forms of S using the Ancestral sequence of the S protein (Hoffmann et al., 2021 ; Kyriakidis et al., 2021; Lamb, 2021) . More recently, the Delta variant spread from India to many countries with great speed in spite of significant proportions of fully vaccinated invididuals in many countries. Delta shows the RBD mutation L452R which appeared independently in several areas of the globe, including in variants Lambda, Kappa, Epsilon, Iota, and contributes to escape neutralization from Abs induced by previously acquired immunity (Deng et al.2021 ). Additionally, mutation P681R in the furin cleavage site of Delta could increase the rate of S1-S2 cleavage, resulting in better transmissibility (Cherian et al., 2021) .

induced strong neutralizing activity in mouse immunogenicity studies, and protected hamsters from SARS-CoV-2 challenge using a virus related to the ancestral isolate (Fluckiger et al. 2021 Employing the same strategy, we produced a new vaccine candidate, VBI-2905a, that expresses a modified prefusion S based on the Beta variant sequence. Consistent with previous studies, VBI-2905a elicited neutralizing antibody responses against the Beta variant which were significantly greater than those induced by VBI-2902a, and responses against the ancestral strain which were comparable to VBI-2902a. Consistent with the role of neutralizing antibody responses as a presumed correlate of protection, greater efficacy was observed in hamsters vaccinated with VBI-2905a relative to VBI-2902a when challenged with the Beta variant. Noteworthy was the observation in an alternative vaccination regimen that priming with VBI-2902a followed by a single booster dose of VBI-2905a induced strong neutralizing antibody responses against the ancestral strain as well as both Beta and Delta VOC.

We also evaluated immunity elicited with a distinct eVLP-based candidate, VBI-2901a, which expresses a modified prefusion S based on the ancestral sequence in addition to the related S proteins from SARS CoV-1 and MERS. Immunization with VBI-2901a induced neutralizing antibody titers against the Beta variant significantly greater than VBI-2902a and comparable to those induced with VBI-2905a, effectively broadening immunity to VOC not contained within the vaccine. Antibody binding and neutralizing titers against an extended panel of variants demonstrated responses typically 3-fold greater than that observed with VBI-2902a. Collectively, these results demonstrate multiple ways to broaden immunity to SARS-CoV-2 VOC.

Expression plasmid for the production of eVLPs expressing SARS-CoV-2 S proteins have been described previously (Fluckiger et al. 2021 ). Briefly, the prefusion modified form of S was obtained by introducing a mutation at the furin cleavage site (RRAR → GSAS) and two Proline at position K986-V987 of the Wuhan reference and swapping the transmembrane cytoplasmic domain with that of the VSV-G protein. VBI-2902a was produced using the Wuhan-Hu-1 spike sequence (Genbank accession number MN908947), and VBI-2905a was produced using the same strategy with S sequence from Beta variant B.1.351 isolate EPI_ISL_911433 (GISAID). Production and purification of eVLPs were conducted as described elsewhere (Fluckiger et al. 2021 ). The preparation of eVLPs expressing either Wuhan reference Spike or Beta variant Spike were formulated in Aluminum phosphate (Alum, Adjuphos® , Invitrogen) to obtain vaccine candidate VBI-2902a and VBI-2905a, respectively. To produce VBI-2901, Two additionnal plasmids were produced that expressed the optimized sequences for full-lenght unmodified S protein from SARS-CoV-1 and MERS-CoV. To produce trivalent eVLPs, HEK-293SF-3F6 were cotransfected with these 2 plasmids together with the plasmid coding for prefusion ancestral SARS-CoV-2 S used for VBI-2902a production, and the MLVGAG plasmid as described. Expression of SARS-CoV-2 S, SARS-CoV-1 S, MERS-CoV S and GAG were determined by Western blot analysis (Supplementary material Fig.S1 ).

Six-to 8-week-old female C57BL/6 mice were purchased from Charles River (St Constant, Quebec Canada). The animals were acclimatized for a period of at least 7 days before any procedures were performed. The animal studies were conducted under ethics protocols approved by the NRC Animal Care Committee. Mice were maintained in a controlled environment in accordance with the "Guide for the Care and Use of Laboratory Animals" at the Animal Research facility of the NRC's Human Health Therapeutics Research Centre (Montreal). Mice were randomly assigned to experimental groups of 10 to 15 mice and received intraperitoneal (IP) injections with 0.5 mL of adjuvanted SARS-CoV-2 eVLPs as described elsewhere (Fluckiger, 2021) . Blood was collected on day -1 before injection and day 14 after each injection for humoral immunity assessment at time of euthanasia.

Syrian golden hamsters (males, 5-6 weeks old) were purchased from Charles River Laboratories Body weights and body temperature were measured at immunization for 3 days and daily from the challenge day. General health conditions were observed daily through the entire study period.

Blood samples were collected as indicated on Fig. 2a .

Anti-SARS-CoV-2 specific IgG binding titers in sera were measured by standard ELISA procedure Determination of Ab binding titers to Spike RBDs was performed using SARS-COV-2 RDB recombinant protein for the specificty of choice as described in Suppl. Table 1 . The detection was completed by adding 3,3',5,5'-tetramethylbenzidine (TMB) substrate solution, and the reaction stopped by adding liquid stop solution for TMB substrate. Absorbance was read at 450 nm in an ELISA microwell plate reader. Data fitting and analysis were performed with SoftMaxPro 5, using a four-parameter fitting algorithm.

Neutralizing activity in mouse serum samples was measured by standard plaque reduction 

VBI-2902a is an eVLP-based vaccine candidate that expresses a modified prefusion SARS-CoV-2 S protein from the ancestral Wu-1 strain, adjuvanted with Alum (Fluckiger et al., 2021) . VBI-2905a expresses a modified prefusion SARS-CoV-2 S protein from the Beta variant and is also adjuvanted with Alum. We immunized mice with 2 injections of VBI-2902a, 2 injections of VBI-2905a, or a first injection of VBI-2902a followed by a second injection of VBI-2905a (heterologous boost). As previously described (Fluckiger et al., 2021) , 2 doses of VBI-2902a induced high levels of neutralizing Ab response against the ancestral Wu-1 strain (GMT = 2,458) which were significantly reduced against the Beta variant (GMT = 94) (Fig.1a-b) . By contrast, VBI-2905a induced Abs that neutralized Beta and ancestral viruses at similar levels in mice, yielding only a 2.2-fold difference with non significant p = 0.1484 (Fig. 1a-b) . Sera from mice in the heterologous boost group cross-neutralized both the Beta variant and the ancestral strain with similar potencies Analysis of Ab binding titers to S protein RBDs was consistent with the neutralization data ( Fig.1c) . VBI-2902a induced high levels (most of the sera >10 6 EPT with GMT 974x10 3 ) of Ab binding titers against the ancestral S RBD with significantly reduced cross-reactivity against the Beta variant RBD (GMT 74x10 3 ), though there was good cross-reactivity against the Delta variant RBD (GMT 616x10 3 ). Antisera from immunization with VBI-2905a showed similar crossreactivty against Ancestral, Delta and Beta RBD (respectively GMT 322x10 3 , 192x10 3 and 217x10 3 ). Animals receiving the heterologous prime boost regimen had similar reactivity to ancestral and Delta RBD as compared with the VBI-2902a group, and similar reactivity to Beta RBD compared to the VBI-2905a group.

Golden Syrian hamsters were intramuscularly vaccinated 3 weeks apart with two doses of eVLP vaccine candidates, comprised of: two doses of VBI-2902a (group VBI-2902a), two doses of VBI-2905a (group VBI-2905a), or a priming dose of VBI-2902a followed by a second, booster dose of VBI-2905a (group heterologous boost) (Fig. 2a) .

Neutralizing activities titers against the ancestral virus were comparable across all groups, including hamsters immunized with 2 doses of the Beta S candidate (VBI-2905a) (Fig.2b) .

Neutralization of the Beta variant was lower after immunization with VBI-2902a, with a significant 9.6-fold decrease of Beta nAb compared to homotypic immunization with VBI-2905a (GMT 99 in VBI-2902a and 1083 in VBI-2905a, p = 0,0033). In contrast, nAb titers against Beta RBD were similar in groups that received either two doses of VBI-2905a or heterologous boosting.

Three weeks after the second immunization, hamsters were exposed to 1x10 5 TCID50 of the Beta variant virus in each nare. In the placebo group, hamsters began losing weight the day after infection which continued until day 6-8. Vaccination with 2 doses of VBI-2902a based on the ancestral S protein induced limited protection against challenge with moderate weight loss recorded until day 4, and only a fraction (3/5) of the animals fully regained their initial body weight after day 7. By contrast, hamsters vaccinated with 2 doses of VBI-2905a exhibited transient weight loss up to day 2-3 and then rapidly regained weight. A similar pattern was observed in hamsters that received VBI-2905a as a boost. As we have observed in previous hamster challenge studies of VBI-2902a, there was a correlation between neutralizing antibody titers against the Beta variant and protection from disease (weight loss) after challenge (data not shown).

We hypothesized that exposing the immune system to multiple spike proteins at the same time might help broaden humoral immunity that could recognize emerging variants or new coronaviruses more phylogenetically distant to the vaccine candidate. To test this hypothesis we produced VBI-2901a, a trivalent eVLP vaccine formulated with Alum, that expresses a prefusion form of the ancestral SARS-CoV-2 S (identical to VBI-2902) with unmodified full length S from SARS-CoV-1 and MERS-CoV (Suppl. Fig. S1 ). Mice that received 2 doses of trivalent VBI-2901a had increased nAb titers (GMT 2915) against the ancestral virus relative to mice that received 2 doses of monovalent VBI-2902a (GMT 831) or VBI-2905a (GMT 448) (Fig. 3a) . Moreover, trivalent VBI-2901a induced neutralization activity against the Beta virus that was equivalent to what was observed in response to homotypic VBI-2905a, and significantly higher than that observed after VBI-2902a vaccination (Fig. 3a) . Neutralization of both Delta and Kappa variant pseudotyped particles confirmed broadened neutralizing immunity elicited by VBI-2901a, with titers approximately 3-fold greater than those induced by VBI-2902a (Fig. 3b) . Consistent with the neutralization activity, VBI-2901a induced higher and/or more consistent levels of Ab binding to the RBD among all variants evaluated, including Beta, Delta, and Lambda (Fig. 3c) . Whereas vaccines based on the ancestral strain of SARS-CoV-2 protect against severe disease caused by variants of concern, variants such as Beta are less sensitive to vaccine-induced immunity and efficacy rates are accordingly lower. This is likely to become more apparent as vaccine-induced immunity wanes and as variants continue to emerge with even greater numbers of mutations. One strategy to address these concerns is to administer booster doses to increase neutralizing antibody titers against the ancestral strain, a subset of which may cross-neutralize variants of concern. We have described three alternate strategies that have the potential to broaden immunity to a greater extent. An eVLP-based candidate based on the Beta variant S protein, VBI-2905a, induces potent immunity against not just the Beta virus, but also against the ancestral strain, though it is less potent against the Delta variant. However, building upon immunity induced against the ancestral strain with a priming dose of VBI-2902a, a single booster dose of VBI-2905a resulted in potent and more balanced neutralizing antibody responses against the ancestral virus, and Beta and Delta variants. Finally, we have described a novel trivalent eVLP candidate, VBI-2901a, which elicited potent and broad immunity against all variants tested, including Beta, Delta, Lambda, and Kappa, with the testing for the potential to neutralize more distantly related viruses currently underway.

(a) Sera from each group were analyzed in PRNT assay with a 90% threshold (PRNT90) using Wu-1 virus and Beta virus as described in Material and Methods. GMT and results from two-tailed Mann-Whitney U-test are indicated. (b) Change in neutralization between Wu-1 and Beta viruses.

Fold change was calculated for each serum as the ratio between reactivity to Ancestral and Beta RBD, Fold change in each group is indicated as the geometric mean preceeded by an arrow.

Statistical analysis was determined using two tailed Wilcoxon test. (c) Ab binding titers were evaluated by ELISA using recombinant Delta RBD as described in Material and Methods.

Statistical significance was determined by Kruskall-Wallis test. Results are represented for each animal in each groups as kinetic of weight change from day 0 to day 14 after infection. One animal from VBI-2905a group was sacrificed at day 7 because of worsening of clinical presentation after a fight in the cage. Significant days of weight loss relative to Saline group (p<0.005) are indicated. Statistical analysis was performed with unpaired non parametric multiple t test using Holm-Šidák method. 

SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma

Positive selection within the genomes of SARS-CoV-2 and other Coronaviruses independent of impact on protein function

Evolutionary origins of the SARS-CoV-2 sarbecovirus lineage responsible for the COVID-19 pandemic

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India. Microorganisms

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant

Detection of neutralizing antibodies with HCV pseudoparticles (HCVpp)

An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity. Vaccine

A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques

SARS-CoV-2 variants, spike mutations and immune escape

351 and P.1 escape from neutralizing antibodies. Cell

European Centre for Disease Prevention and Control, SARS-Co-V-2 variants of concern as of

World Health Organization, Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus

Enveloped virus-like particle expression of human cytomegalovirus glycoprotein B antigen induces antibodies with potent and broad neutralizing activity. Clin Vaccine Immunol

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines

BNT162b2 mRNA COVID-19 Vaccine: First Approval

Spike mutation D614G alters SARS-CoV-2 fitness

Implications of altered replication fidelity on the evolution and pathogenesis of coronaviruses

V2 escapes neutralization by South African COVID-19 donor plasma

A new coronavirus associated with human respiratory disease in China

Erratum in: Nature

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

received 2 IP injections 3 weeks apart , of VBI-2902a or VBI-2905a or a first injection of VBI-2902a followed by a second injection of VBI-2905a (Heterologous boost), each containing 0.1 µg of S. Blood was collected at day 14 after the second injection for monitoring of the humoral response. EPT measured by PRNT90 against Wu-1 virus and Beta variant. GMT are indicated above each group. (b) Neutralization of pseudoparticles expressing S from Wu-1 virus, or Delta or Kappa variants are represented as half-maximum inhibitory dilutions (Neutralization ID50). Geometric means are indicated above each panel. Due to technical limitations, only 8 sera per groups were tested against Wu-1 and Kappa pseudoparticles and 4 sera against Delta pseudoparticles. Sera were randomly picked. (c) Ab binding titers measured in ELISA

The authors want to thank Adam Asselin, Matthew Yorke, Teresa Daoud, Rebecca Wang, Gillian Lampkin (VBI vaccines) for outstanding technical support; NRC Animal Resources Group and the VIDO Saskatchewan team for remarkable care with animal experiments.

The work performed in this manuscript was supported by the Coalition for Epidemic Preparedness Innovations (CEPI)